That typically triggers the classical pathway, which recruits macrophages and other inflammatory cells. True North’s lead candidate, TNT009 puts the breaks on that cascade, Stagliano said.

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...

Recently, the company has announced the following additions to the pipeline: 1) ARO-C3: This program is targeting complement component 3 (C3). The complement pathway is a part of the innate immune ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at ...

The classical complement pathway is activated upon antibodies binding to viral proteins or autoantibodies in the body’s tissue. In the present study, ...

Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...